Regulation of microvascular thromboembolism in vivo

Microcirculation

Volumn 12, Issue 3, 2005, Pages 287-300

  Oude Egbrink, Mirjam G A ^a   Van Gestel, Miriam A ^a   Broeders, Martijn A W ^b   Tangelder, Geert Jan ^c   Heemskerk, Johan M W ^a   Reneman, Robert S ^a   Slaaf, Dick W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RIJNLAND HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood platelets; Endothelium; Microcirculation; Nitric oxide; Prostacyclin; Wall shear rate; Wall shear stress

Indexed keywords

ADENOSINE DIPHOSPHATE; CD39 ANTIGEN; FIBRINOGEN; FRACTALKINE; GELATINASE A; GELATINASE B; HEPARAN SULFATE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROSTAGLANDIN; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VON WILLEBRAND FACTOR;

ANTICOAGULATION; ARTERIOLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL ACTIVATION; CELL INTERACTION; DISEASE CONTROL; DISEASE COURSE; ENDOTHELIUM CELL; EVIDENCE BASED MEDICINE; HUMAN; IN VIVO STUDY; MICROANGIOPATHY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; VASCULAR ENDOTHELIUM; VENULE; WESTERN HEMISPHERE;

ANIMALS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HUMANS; MICROCIRCULATION; STRESS, MECHANICAL; THROMBOEMBOLISM;

ANIMALIA; THROMBUS;

EID: 18844406966     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1080/10739680590925628     Document Type: Review

References (119)

1. Albrecht EW, Stegeman CA, Heeringa P, Henning BE, van Goor H. (2003). Protective role of endothelial nitric oxide synthase. J Pathol 199:8-17.
2. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. (2002). CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism. Nat Med 8:247-252.
3. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB. (2003). P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112:398-406.
4. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, Collen D, Dahlback B, Carmeliet P. (2001). Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7:215-221.
5. Augustin HG, Kozian DH, Johnson RC. (1994). Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 16:901-906.
6. Azizzadeh B, Buga GM, Berke GS, Larian B, Ignarro LJ, Blackwell KE. (2003). Inhibitors of nitric oxide promote microvascular thrombosis. Arch Facial Plast Surg 5:31-35.
7. Badimon L. (2001). Atherosclerosis and thrombosis: lessons from animal models. Thromb Haemost 86:356-365.
8. Bajzar L. (2000). Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 20:2511-2518.
9. Beguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. (1999). Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 93:564-570.
10. Bergqvist D. (1974). Haemostatic plug formation in the rabbit mesentery: a methodological study. Ups J Med Sci 79:28-38.
11. Bevers EM, Comfurius P, Zwaal RF. (1991). Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 5:146-154.
12. Boegehold MA. (1998). Heterogeneity of endothelial function within the circulation. Curr Opin Nephrol Hypertens 7:71-78.
13. Boergen KP, Birngruber R, Hillenkamp F. (1981). Laser-induced endovascular thrombosis as a possibility of selective vessel closure. Ophthalmic Res 13:139-150.
14. Borgdorff P, Fekkes D, Tangelder GJ. (2002). Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 106:2588-2593.
15. Born GVR. (1984). Platelets and blood vessels. J Cardiovasc Pharmacol 6:S706-S713.
16. Brass L. (2004). Fifty (or more) ways to leave your platelets (in a thrombus). Arterioscler Thromb Vasc Biol 24:989-991.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. (2001). Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661-690.
18. Broeders MAW, Tangelder GJ, Slaaf DW, Reneman RS, oude Egbrink MGA. (1998). Endogenous nitric oxide protects against thromboembolism in venules but not in arterioles. Arterioscler Thromb Vasc Biol 18:139-145.
19. Broeders MAW, Doevendans PA, Bekkers BCAM, Bronsaer R, van Gorsel E, Heemskerk JWM, oude Egbrink MCA, van Breda E, Reneman RS, van der Zee R. (2000). Nebivolol: a third generation beta-blocker that augments vascular nitric oxide release: endothelial b2-adrenergic receptor-mediated nitric oxide production. Circulation 102:677-684.
20. Broeders MAW, Doevendans PA, Maessen JG, van Gorsel E, oude Egbrink MGA, Daemen MJAP, Tangelder GJ, Reneman RS, van der Zee R. (2001). The human internal mammary artery releases more nitric oxide in response to vascular endothelial growth factor than the human saphenous vein. J Thorac Cardiovasc Surg 122:305-309.
21. Broeders MAW, Tangelder GJ, Slaaf DW, Reneman RS, oude Egbrink MGA. (2001). Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules. Arterioscler Thromb Vasc Biol 21:163-169.
22. Broeders MAW, Tangelder GJ, Slaaf DW, Reneman RS, oude Egbrink MCA. (2002). Hypercholesterolemia enhances thromboembolism in arterioles but not in venules; complete reversal by L-arginine. Arterioscler Thromb Vasc Biol 22:680-685.
23. Busse R, Fleming I. (2003). Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci 24:24-29.
24. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. (2003). Antithrombotic activity of TNF-alpha. J Clin Invest 112:1589-1596.
25. Cattaneo M, Gachet C. (1999). ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 19:2281-2285.
26. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541.
27. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. (1998). Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561.
28. Conley PB, Delaney SM. (2003). Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol 10:333-338.
29. Coughlin SR. (2001). Protease-activated receptors in vascular biology. Thromb Haemost 86:298-307.
30. Davidge ST, Pitt BR, McLaughlin MK, Roberts JM, Johnson BA. (1999). Biphasic stimulation of prostacyclin by endogenous nitric oxide (NO) in endothelial cells transfected with inducible NO synthase. Gen Pharmacol 33:383-387.
31. de Nucci G, Gryglewski RJ, Warner TD, Vane JR. (1988). Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 85:2334-2338.
32. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. (1998). A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 95:9524-9529.
33. Dörffler-Melly J, Schwarte LA, Ince C, Levi M. (2000). Mouse models of focal arterial and venous thrombosis. Basic Res Cardiol 95:503-509.
34. Dorsam RT, Kunapuli SP. (2004). Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113:340-345.
35. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. (2002). Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 8:1175-1181.
36. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW, Davidge ST. (1999). Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 82:1730-1735.
37. Garlanda C, Dejana E. (1997). Heterogeneity of endothelial cells; specific markers. Arterioscler Thromb Vasc Biol 17:1193-1202.
38. Gawaz M. (2004). Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61:498-511.
39. Gebb S, Stevens T. (2004). On lung endothelial cell heterogeneity. Microvasc Res 68:1-12.
40. Gerritsen ME. (1996). Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc Res 32:720-732.
41. Hackeng TM, van't Veer C, Meijers JC, Bouma BN. (1994). Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 269:21051-21058.
42. Heemskerk JWM, Bevers EM, Lindhout T. (2002). Platelet activation and blood coagulation. Thromb Haemost 88:186-193.
43. Hellums JD. (1994). 1993 Whitaker Lecture: biorheology in thrombosis research. Ann Biomed Eng 22:445-455.
44. Ignarro LJ. (2000). Nitric Oxide: Biology and Pathobiology. San Diego: Academic Press.
45. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. (2003). CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92:1041-1048.
46. 2: A biochemical perspective. Prostglandins Leukotrienes Med 37:219-234.
47. Jackson SP, Nesbitt WS, Kulkarni S. (2003). Signaling events underlying thrombus formation. J Thromb Haemost 1:1602-1612.
48. Jang EK, Azzam JE, Dickinson NT, Davidson MM, Haslam RJ. (2002). Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside. Br J Haematol 117:664-675.
49. Johnson EN, Brass LF, Funk CD. (1998). Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc Natl Acad Sci USA 95:3100-3105.
50. Kawashima S, Yokoyama M. (2004). Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 24:998-1005.
51. Knowles RG, Moncada S. (1994). Nitric oxide synthases in mammals. Biochem J 298:249-258.
52. Kuijpers MJ, Schulte V, Bergmeier W, Lindhout T, Brakebusch C, Offermanns S, Fassler R, Heemskerk JW, Nieswandt B. (2003). Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J 17:685-687.
53. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. (2000). A revised model of platelet aggregation. J Clin Invest 105:783-791.
54. Kumada T, Dittman WA, Majerus PW. (1988). A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 71:728-733.
55. Kurz KD, Main BW, Sandusky GE. (1990). Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 60:269-280.
56. Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. (1999). Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 104:1731-1737.
57. Li Z, Ajdic J, Eigenthaler M, Du X. (2003). A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood 101:4423-4429.
58. Lindberg RA, Slaaf DW, Miller FN. (1994). Involvement of nitric oxide and cyclooxygenase products in photoactivation-induced microvascular occlusion. Mircovasc Res 47:203-221.
59. Loscalzo J. (2001). Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88:756-762.
60. Mann KG, Brummel K, Butenas S. (2003). What is all that thrombin for? J Thromb Haemost 1:1504-1514.
61. Marcus A, Broekman M, Drosopoulos J, Pinsky D, Islam N, Gayle R 3rd, Maliszewski C. (2001). Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol 21:178-182.
62. Massberg S, Enders G, Matos FC, Tomic LI, Leiderer R, Eisenmenger S, Messmer K, Krombach F. (1999). Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 94:3829-3838.
63. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D, Heinzmann U, Nieswandt B. (2003). A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 197:41-49.
64. Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K, Kersting J, Schulz C, Muller I, Besta F, Nieswandt B, Heinzmann U, Walter U, Gawaz M. (2004). Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 103:136-142.
65. Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M, Schneider S, Besta F, Muller I, Hu B, Langer H, Kremmer E, Rudelius M, Heinzmann U, Ungerer M, Gawaz M. (2004). Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18:397-399.
66. Maurice DH, Haslam RJ. (1990). Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671-681.
67. Mehta SR, Yusuf S. (2003). Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 41:79S-88S.
68. Moncada S. (1982). Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980: biological importance of prostacyclin. Br J Pharmacol 76:3-31.
69. G-Nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 99:408-412.
70. Murray CJL, Lopez AD. (1997). Mortality by cause for eight regions of the world: global burden of disease study. Lancet 349:1269-1276.
71. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. (2000). Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 106:385-392.
72. Nichols TC, Bellinger DA, Reddick RL, Read MS, Koch GG, Brinkhous KM, Griggs TR. (1991). Role of von Willebrand factor in arterial thrombosis: studies in normal and von Willebrand disease pigs. Circulation 83:IV56-IV64.
73. Nowak J, FitzGerald GA. (1989). Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 83:380-385.
74. O'Brien JR. (1990). Shear-induced platelet aggregation. Lancet 335:711-713.
75. oude Egbrink MGA, Tangelder GJ, Slaaf DW, Reneman RS. (1988). Thromboembolic reaction following wall puncture in arterioles and venules of the rabbit mesentery. Thromb Haemostas 59:23-28.
76. oude Egbrink MGA, Tangelder GJ, Slaaf DW, Reneman RS. (1991). Fluid dynamics and the thromboembolic reaction in mesenteric arterioles and venules. Am J Physiol 260:H1826-H1833.
77. oude Egbrink MGA, Tangelder GJ, Slaaf DW, Reneman RS. (1993). Different roles of prostaglandins in thromboembolic processes in arterioles and venules in vivo. Thromb Haemostas 70:826-833.
78. Palmer RM, Ashton DS, Moncada S. (1988). Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666.
79. Paul BZ, Jin J, Kunapuli SP. (1999). Molecular mechanism of thromboxane A(2)-induced platelet aggregation: essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 274:29108-29114.
80. Pinto A, Sorrentino R, Sorrentino L. (1990). Levamisole inhibits in vivo rat platelet aggregation by a release of prostacyclin-like factor. Gen Pharmacol 21:255-259.
81. Pirich C, Efthimiou Y, O'Grady J, Sinzinger H. (1997). Hyperalphalipoproteinemia and prostaglandin I2 stability. Thromb Res 88:41-49.
82. Radomski MW, Palmer RM, Moncada, S. (1987). The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92:639-646.
83. Radomski MW, Palmer RM, Moncada S. (1987). Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 92:181-187.
84. Reneman RS, Woldhuis B, oude Egbrink MGA, Slaaf DW, Tangelder GJ. (1992). Concentration and velocity profiles of blood cells in the microcirculation. In: Advances in cardiovascular engineering (NHC Hwang, VT Turitto, MET Yen Eds). New York: Plenum Press, 25-40.
85. Resnick N, Yahav H, Shay-Salit A, Shushy M, Schubert S, Zilberman LC, Wofovitz E. (2003). Fluid shear stress and the vascular endothelium: for better and for worse. Prog Biophys Mol Biol 81:177-199.
86. Rosen ED, Raymond S, Zollman A, Noria F, Sandoval-Cooper M, Shulman A, Merz JL, Castellino FJ. (2001). Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol 158:1613-1622.
87. Rosenberg RD, Aird WC. (1999). Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340:1555-1564.
88. Rosenberg RD. (2001). Vascular-bed-specific hemostasis and hypercoagulable states: clinical utility of activation peptide assays in predicting thrombotic events in different clinical populations. Thromb Haemost 86:41-50.
89. Ruggeri ZM. (2002). Platelets in atherothrombosis. Nat Med 8:1227-1234.
90. Ruggeri ZM. (2003). Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1:1335-1342.
91. Rumbaut RE, Randhawa JK, Smith CW, Burns AR. (2004). Mouse cremaster venules are predisposed to light/dye-induced thrombosis independent of wall shear rate, CD18, ICAM-1 or P-selectin. Microcirculation 11:239-247.
92. Salvemini D, Currie MG, Mollace V. (1996). Nitric oxide-mediated cyclooxygenase activation: a key event in the antiplatelet effects of nitrovasodilators. J Clin Invest 97:2562-2568.
93. Salvemini D. (1997). Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 53:576-582.
94. Sargeant P, Sage SO. (1994). Calcium signalling in platelets and other nonexcitable cells. Pharmacol Ther 64:395-443.
95. Sato M, Ohshima N. (1984). Platelet thrombus induced in vivo by filtered light and fluorescent dye in mesenteric microvasculature of rat. Thromb Res 35:319-334.
96. Schafer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, Ertl G, Walter U, Bauersachs J. (2004). Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 103:407-412.
97. Seiffge D, Kremer E. (1986). Influence of ADP, blood flow velocity, and vessel diameter on the laser-induced thrombus formation. Thromb Res 42:331-341.
98. Selwyn AP. (2003). Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 91:3H-11H.
99. Sinzinger H, Rauscha F, Fitscha P, Granegger S. (1990). Prevalence of a shortened prostacyclin half-life in plasma in healthy adults: results of a screening investigation. Am J Hematol 33:139-141.
100. Suzuki H, Swei A, Zweifach BW, Schmid-Schöenbein GW. (1995). In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats: hydroethidine microfluorography. Hypertension 25:1083-1089.
101. Tangelder GJ, Teirlinck HC, Slaaf DW, Reneman RS. (1985). Distribution of blood platelets flowing in arterioles. Am J Physiol 248:H318-H323.
102. Tangelder GJ, Slaaf DW, Muijtjens AAM, Arts T, oude Egbrink MGA, Reneman RS. (1986). Velocity profiles of blood platelets and red blood cells flowing in arterioles of the rabbit mesentery. Circ Res 59:505-514.
103. Tangelder GJ, Slaaf DW, Arts T, Reneman RS. (1988). Wall shear rate in arterioles in vivo: least estimates from platelet velocity profiles. Am J Physiol 254:H1059-H1064.
104. Tangelder GJ, oude Egbrink MGA, Slaaf DW, Reneman RS. (1989). Blood platelets: an overview. J Reconstr Microsurg 5:161-171.
105. Triggle CR, Hollenberg M, Anderson TJ, Ding H, Jiang Y, Ceroni L, Wiehler WB, Ng ES, Ellis A, Andrews K, McGuire JJ, Pannirselvam M. (2003). The endothelium in health and disease - a target for therapeutic intervention. J Smooth Muscle Res 39:249-267.
106. Uematsu M, Ohara Y, Navas JP, Nishida K, Murphy TJ, Alexander RW, Nerem RM, Harrison DG. (1995). Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. Am J Physiol 269:C1371-C1378.
107. van Gestel MA, Heemskerk JWM, Slaaf DW, Heijnen VVT, Sage SO, Reneman RS, oude Egbrink MGA. (2002). Real-time detection of activation patterns in individual platelets during thromboembolism in vivo: differences between thrombus growth and embolus formation. J Vasc Res 39:534-543.
108. van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG. (2003). In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 23:518-523.
109. van Gestel MA. (2004). Adp and Thrombin During Thromboembolism in Vivo: a Vital Imaging Approach. Thesis, Maastricht University.
110. van Hinsbergh VW. (2001). The endothelium: vascular control of haemostasis. Eur J Obstet Gynecol Reprod Biol 95:198-201.
111. Vandeplassche G, Bernier M, Thone F, Borgers M, Kusama Y, Hearse DJ. (1990). Singlet oxygen and myocardial injury: ultrastructural, cytochemical and electrocardiographic consequences of photoactivation of rose bengal. J Mol Cell Cardiol 22:287-301.
112. Vane JR, Botting RM. (1995). Pharmacodynamic profile of prostacyclin. Am J Cardiol 75:3a-10a.
113. Vink H, Constantinescu AA, Spaan JA. (2000). Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion. Circulation 101:1500-1502.
114. 2 synthase. Arch Biochem Biophys 347:174-180.
115. Wagner L, Hoey JG, Erdely A, Boegehold MA, Baylis C. (2001). The nitric oxide pathway is amplified in venular vs arteriolar cultured rat mesenteric endothelial cells. Microvasc Res 62:401-409.
116. Woldhuis B, Tangelder GJ, Slaaf DW, Reneman RS. (1992). Concentration profile of blood platelets differs in arterioles and venules. Am J Physiol 262:H1217-H1223.
117. Wu KK, Chen YC, Fordham E, Ts'Ao CH, Rayudu G, Matayoshi D. (1981). Differential effects of two doses of aspirin on platelets-vessel wall interaction in vivo. J Clin Invest 68:382-387.
118. Yang Z, Arnet U, Bauer E, von Segesser L, Siebenmann R, Turina M, Luscher TF. (1994). Thrombin-induced endothelium-dependent inhibition and direct activation of platelet-vessel wall interaction: role of prostacyclin, nitric oxide, and thromboxane A2. Circulation 89:2266-2272.
119. Ziegler T, Silacci P, Harrison VJ, Hayoz D. (1998). Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension 32:351-355.